. Correction to: Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study'' by Subbiah et al. Thyroid 2024;34(1):26-40; doi: 10.1089/thy.2023.0363 Thyroid 2024 Apr 16. doi: 10.1089/thy.2023.0363.
PMID: 38625021